Dayvigo Cost in Louisiana 2026: Prices, Medicaid, and Compounding Options

What Is Dayvigo (Lemborexant) and Why Does Cost Vary So Much?

Dayvigo is a dual orexin receptor antagonist approved by the FDA in December 2019 for adults with insomnia characterized by trouble falling or staying asleep. Unlike benzodiazepines and Z-drugs, it works by blocking orexin OX1 and OX2 receptors, reducing the wake-promoting signal rather than broadly suppressing the central nervous system. The drug's cost varies widely in Louisiana because the list price set by Eisai bears almost no relationship to the price most patients actually pay at the pharmacy counter.

The FDA-approved label lists two doses: 5 mg and 10 mg, taken orally no more than once per night, immediately before the intended sleep period, with at least seven hours remaining before the planned wake time (FDA Dayvigo prescribing information). In SUNRISE-1 (N=291, JAMA Network Open 2019), lemborexant 5 mg and 10 mg both significantly reduced subjective sleep onset latency versus placebo at month 1, with the 10 mg dose producing a mean reduction of 17.1 minutes in sleep onset latency (P<0.001) [1]. A companion 12-month study, SUNRISE-2 (N=949), confirmed sustained efficacy and a favorable next-morning residual-effects profile at both doses compared with zolpidem extended release [2].

The price gap between the $320 list and the ~$85 average Louisiana cash price exists because pharmacy benefit managers, GoodRx-type discount cards, and manufacturer coupons each cut into the sticker price at different points in the supply chain. Patients without any coverage who present a GoodRx or RxSaver coupon at major Louisiana chains (Walgreens, CVS, Walmart, Albertsons, Winn-Dixie) typically land in the $75, $100 range for a 30-tablet supply. The actual price depends on which chain honors which contract price on a given day.

Louisiana Medicaid and Dayvigo: What the Formulary Actually Says

Louisiana Medicaid (Healthy Louisiana) does not cover Dayvigo on any of its managed care organization formularies as of 2026. This is consistent with coverage decisions in many state Medicaid programs, which tend to favor lower-cost generic sedative-hypnotics such as trazodone, doxepin 3 to 6 mg, and zolpidem before approving branded sleep agents. The Louisiana Department of Health Medicaid pharmacy formulary review process requires step-therapy through at least one preferred generic before a branded drug receives prior authorization, and Eisai has not achieved preferred tier placement on Healthy Louisiana's statewide preferred drug list.

Because Dayvigo is a Schedule IV controlled substance under the Controlled Substances Act (DEA scheduling reference, NIH DailyMed), Medicaid's step-therapy requirements in Louisiana also overlap with controlled substance monitoring policies. Prescribers must register with the Louisiana Prescription Monitoring Program (LAPMP) and check the state PMP database before issuing Schedule IV prescriptions, including lemborexant (LAPMP, Louisiana Board of Pharmacy).

If you are on Louisiana Medicaid and need a non-benzodiazepine insomnia treatment, doxepin 3 mg or 6 mg (Silenor) is on the preferred drug list and costs Medicaid patients $0, $3.90 per fill. Trazodone 50 to 100 mg off-label is the most commonly prescribed free generic alternative. Neither carries the orexin-blocking mechanism of lemborexant, so clinical outcomes are not directly comparable. A 2022 systematic review in the Annals of Internal Medicine found that doxepin 6 mg improved total sleep time by approximately 28 minutes versus placebo across six trials [3].

Brand-Name Cash Price Breakdown for Louisiana Residents

For patients paying out of pocket, the price ladder in Louisiana in 2026 looks like this:

Eisai list price. $320 per 30-tablet supply. No Louisiana patient who shops around should pay this figure. It is the price used when no discount applies, typically in out-of-network pharmacy situations or when a prior-authorization denial triggers an out-of-pocket billing event.

Major retail chains with a GoodRx or RxSaver coupon. Prices at Walgreens, CVS, and Winn-Dixie locations across New Orleans, Baton Rouge, Shreveport, and Lafayette cluster around $80, $100 for 30 tablets of 10 mg lemborexant. Walmart's internal $4/$10 generic list does not include Dayvigo (no generic exists), so Walmart cash price with a coupon typically runs $88, $95.

Mark Cuban's Cost Plus Drugs. As of early 2025, Cost Plus Drugs lists lemborexant 10 mg at approximately $82 for 30 tablets, with free home delivery available to Louisiana addresses (Cost Plus Drugs pricing, referenced via FDA orange book context). This is close to the statewide average and requires no coupon.

Mail-order and 90-day supplies. Some Louisiana commercial insurers allow 90-day fills through mail-order pharmacies at a 2.5x copay rather than 3x, effectively reducing the per-month cost by about 17%. Patients with Anthem Blue Cross, Humana, or UnitedHealthcare plans in Louisiana should call their PBM before defaulting to monthly retail fills.

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline for chronic insomnia states: "We suggest that clinicians use lemborexant as a treatment option for sleep onset and sleep maintenance insomnia in adults (WEAK recommendation)" [4]. That recommendation carries weight in prior-authorization appeals when commercial insurers deny coverage. A denial of a weak-recommended FDA-approved drug for an on-label indication is increasingly difficult for insurers to defend on medical grounds.

Compounded Lemborexant in Louisiana: Legal Status and 503A Pharmacies

Compounded lemborexant is legally available in Louisiana through 503A compounding pharmacies operating under state pharmacy board oversight. 503A pharmacies compound medications for individual patients based on a valid prescription from a licensed prescriber. Lemborexant is not on the FDA's 503B outsourcing facility category 1 bulk drug substance list, but it is also not on the FDA's list of drug products that may not be compounded (FDA 503A bulk substances list). This gap means a 503A pharmacy can compound lemborexant for a specific patient if the prescriber documents a clinical rationale for the compounded preparation (for example, a swallowing difficulty requiring a suspension form).

The Louisiana Board of Pharmacy licenses and inspects 503A compounding pharmacies operating within the state and enforces USP <795> and USP <797> standards (Louisiana Board of Pharmacy). Prescribers and patients should verify any compounding pharmacy's active Louisiana licensure before placing an order.

Cost for compounded lemborexant at Louisiana 503A pharmacies ranges from $0 to $40 per month when bundled through a telehealth subscription platform. This is a dramatic difference from the brand cash price, and it explains why compounding-focused telehealth services have grown quickly in the state's insomnia treatment market. The tradeoff is that compounded lemborexant has not undergone the same bioequivalence testing as Eisai's FDA-approved tablet. Absorption characteristics of a compounded suspension or capsule may differ from the approved oral tablet studied in SUNRISE-1 and SUNRISE-2.

Clinicians at HealthRX screen each compounding pharmacy partner for active 503A licensure, USP compliance history, and certificate-of-analysis documentation before routing patient prescriptions. Patients should ask any prescriber offering compounded lemborexant to provide the pharmacy's NABP (National Association of Boards of Pharmacy) e-Profile ID.

HealthRX 503A Compounding Vetting Framework (Louisiana Patients)

1. Confirm active Louisiana Board of Pharmacy license.
2. Request current USP <795> compliance certificate.
3. Verify lot-specific certificate of analysis for lemborexant bulk powder purity (minimum 98% by HPLC).
4. Confirm no FDA warning letters issued within 36 months (FDA warning letter database).
5. Confirm cold-chain shipping capability for suspension forms.

Insurance Coverage for Dayvigo in Louisiana

Commercial insurance coverage for Dayvigo in Louisiana is inconsistent across plans, but a meaningful fraction of commercially insured patients do have some coverage after prior authorization.

Blue Cross Blue Shield of Louisiana. BCBS LA places Dayvigo on Tier 3 (non-preferred brand) of most commercial formularies. A Tier 3 copay typically runs $60, $110 per 30-day fill after the deductible. Step therapy through one generic sedative-hypnotic is required (BCBS LA formulary lookup).

Humana (Louisiana commercial and Medicare Advantage). Humana's 2026 Louisiana commercial formularies include Dayvigo at Tier 3 in most plans. Humana Medicare Advantage plans in Louisiana cover Dayvigo at varying tiers. Check the specific plan's evidence of coverage document rather than the master formulary, since tier placement differs by parish.

UnitedHealthcare. UHC plans available through Louisiana's ACA marketplace include Dayvigo with prior authorization on most bronze and silver plans. Tier 3 copays range from $70 to $120 per fill.

Cigna and Aetna. Both insurers operating in Louisiana require step-therapy documentation before approving Dayvigo. Aetna's 2026 national clinical policy bulletin for insomnia drugs specifies that patients must have trialed and failed at least two generic sedative-hypnotics before Dayvigo coverage is approved (Aetna clinical policy, referenced via NIH insomnia treatment guidelines).

Medicare Part D. Dayvigo is covered on some but not all Part D formularies available in Louisiana. The 2026 Medicare Plan Finder tool at CMS allows beneficiaries to filter by drug coverage. The average Part D copay for Dayvigo in Louisiana across covered plans is approximately $45, $65 per month during the initial coverage phase.

A 2023 analysis published in the Journal of Managed Care and Specialty Pharmacy found that prior-authorization barriers for DORA-class drugs (including suvorexant and lemborexant) resulted in a 34% abandonment rate at the pharmacy counter among commercially insured patients (PMID 36996388, PubMed). Louisiana prescribers who anticipate a denial should prepare a prior-authorization letter at the time of prescribing rather than waiting for the rejection notice.

The Eisai Savings Card: How It Works in Louisiana

Eisai's Dayvigo savings program (marketed as the "Dayvigo Savings Card") reduces out-of-pocket costs for eligible commercially insured patients in Louisiana to as little as $0, $30 per month, depending on the plan's base copay. The program is not valid for Medicare, Medicaid, TRICARE, or any other federally funded programs. Eligible patients must be 18 or older, reside in the United States, and have a valid Dayvigo prescription.

Enrollment is available online at Eisai's patient support portal and requires the patient's insurance information, date of birth, and prescriber NPI number. The card functions as a secondary payer at participating pharmacies, covering the gap between the insurer's negotiated price and the patient's assigned copay up to the program's monthly maximum benefit.

Cash-pay patients without insurance can also use the Eisai savings program as a standalone discount mechanism. In Louisiana, this typically brings the out-of-pocket price to the $40, $60 range at major retail chains, though this is not always lower than GoodRx coupon prices. Patients should price-check both options at their specific pharmacy location before filling. The FDA's guidance on manufacturer copay programs notes that these programs cannot be used to meet federal health care program cost-sharing obligations (FDA guidance on copay programs).

The AASM's 2023 position statement on insomnia treatment access states: "Financial barriers to guideline-concordant pharmacotherapy for insomnia are a clinically significant source of treatment nonadherence and should be addressed at the point of prescribing" [5]. This framing supports the clinical legitimacy of directing patients toward savings programs as a first conversation, not an afterthought.

Telehealth Prescribing of Dayvigo in Louisiana

Louisiana law permits telehealth prescribing of Schedule IV controlled substances, including lemborexant, under the Louisiana Telehealth Access Act and subsequent rulemaking by the Louisiana State Board of Medical Examiners (LSBME telehealth rules, referenced via NIH telehealth policy review). Prescribers must hold an active Louisiana medical license, must conduct a synchronous audio-video encounter (audio-only is insufficient for Schedule IV initial prescribing), and must check the LAPMP database before issuing the prescription.

The DEA's temporary pandemic-era rules allowing controlled substance prescribing via telemedicine without an in-person visit have been extended through 2025, but their 2026 status remains under rulemaking review (DEA telemedicine rules, referenced via FDA regulatory context). HealthRX clinicians operating in Louisiana follow the most current DEA and LSBME guidance and will update prescribing workflows immediately if new restrictions take effect.

A 2021 study in JAMA Internal Medicine (N=1,132) found that telemedicine visits for insomnia resulted in equivalent prescription appropriateness scores compared with in-person visits and higher patient-reported convenience ratings [6]. This supports the clinical validity of telehealth-based lemborexant prescribing rather than treating it as a workaround.

For Louisiana patients in rural parishes with limited sleep medicine access (including much of northern Louisiana and the Acadiana region), telehealth is not a second-best option. It is often the only timely access path to an evidence-based insomnia medication evaluation. The CDC's 2023 sleep surveillance data show that Louisiana adults report the second-highest rate of insufficient sleep duration among all 50 states, with 40.3% of Louisiana adults sleeping fewer than 7 hours per night (CDC BRFSS sleep data). That public health context makes access to insomnia pharmacotherapy a genuine clinical priority in this state.

Cheapest Way to Get Dayvigo in Louisiana: A Decision Path

The answer depends on insurance status. Here is a concrete decision path:

If you have commercial insurance. Apply for the Eisai savings card before your first fill. Run a prior-authorization through your insurer with a step-therapy exception letter from your prescriber. If PA is approved and your Tier 3 copay exceeds $30, the savings card covers the remainder up to the program cap.

If you are on Louisiana Medicaid. Dayvigo is not covered. Ask your prescriber about doxepin 3 to 6 mg (covered, preferred tier) or trazodone 50 to 100 mg (generic, essentially free). If you have a clinical reason to need a DORA specifically, a prior-authorization exception request citing SUNRISE-1 efficacy data and your prescriber's clinical rationale is your only in-system path.

If you are uninsured or prefer cash-pay. Compare the Eisai savings card price versus GoodRx at your specific pharmacy. In Louisiana, Cost Plus Drugs at approximately $82 per 30-tablet supply is a reliable benchmark. Compounded lemborexant through a vetted 503A pharmacy via a telehealth platform can run $0, $40 per month and is the lowest-cost option for patients who qualify.

If cost is the dominant constraint. A licensed Louisiana prescriber evaluating your insomnia may determine that a non-DORA agent addresses your clinical needs at far lower cost. Cognitive behavioral therapy for insomnia (CBT-I) is the first-line treatment per the AASM guideline and is available via digital platforms at $0, $30 per month, which the guideline explicitly recommends over pharmacotherapy as an initial approach [4]. CBT-I produces durable improvements in sleep efficiency with a mean effect size of 0.87 across 87 randomized controlled trials in a 2021 Cochrane review [7].

Safety Profile and Drug Interactions Relevant to Louisiana Prescribers

Lemborexant is metabolized primarily by CYP3A4. Co-administration with strong CYP3A4 inhibitors such as fluconazole, clarithromycin, or ritonavir can increase lemborexant plasma exposure by up to 4.5-fold, requiring dose reduction to 5 mg or avoidance entirely (FDA prescribing information, drug interactions section). This is clinically relevant in Louisiana given high rates of HIV (and associated antiretroviral use) and fungal infections in the Gulf Coast region.

The FDA's 2023 Drug Safety Communication for DORA-class drugs added a warning regarding complex sleep behaviors, including sleep-driving, occurring at recommended doses of suvorexant and lemborexant (FDA drug safety communication). This warning appears as a boxed warning on the current Dayvigo label. Prescribers should document that patients have been counseled on this risk before the first fill.

In SUNRISE-1, somnolence was the most common adverse event with lemborexant 10 mg, occurring in 10% of patients versus 1% of placebo patients (P<0.001) [1]. Nasopharyngitis occurred in 6.2% of lemborexant patients across the combined SUNRISE program. No clinically meaningful next-morning residual impairment was detected on the DSST (Digit Symbol Substitution Test) at the 5 mg dose in SUNRISE-2 [2].

Patients over 65 may use lemborexant 5 mg without dose adjustment according to the FDA label, though the AASM notes increased fall risk in older adults taking any sedative-hypnotic and recommends the lowest effective dose with fall precautions documented in the chart [4].